Katherine E. Bunge

Katherine E. Bunge

Obstetrics and Gynecology

3601 5th Avenue, Suite 700
Pittsburgh, PA 15213

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Comparing BD Affirm VPIII to Xpert Xpress MVP and BD MAX Vaginal Panel for the diagnosis of vaginal infections.

Comparing BD Affirm VPIII to Xpert Xpress MVP and BD MAX Vaginal Panel for the diagnosis of vaginal infections.

Journal: Microbiology spectrum

Published: July 28, 2026

Randomized Study of Usual Care Versus Xpert ® Xpress Multiplex Vaginal Panel at the Point-of-Care for Accurate Diagnosis and Appropriate Treatment of Vaginal Infections.

Randomized Study of Usual Care Versus Xpert ® Xpress Multiplex Vaginal Panel at the Point-of-Care for Accurate Diagnosis and Appropriate Treatment of Vaginal Infections.

Journal: Sexually transmitted diseases

Published: May 12, 2026

Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine.

Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine.

Journal: Open forum infectious diseases

Published: August 20, 2025

Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial.

Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial.

Journal: The lancet. HIV

Published: June 19, 2025

Advancing ethical biomedical HIV prevention research for pregnant and lactating people.

Advancing ethical biomedical HIV prevention research for pregnant and lactating people.

Journal: AIDS (London, England)

Published: April 04, 2025

Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.

Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.

Journal: The Pediatric infectious disease journal

Published: January 08, 2025

Infant Antibodies After Maternal COVID-19 Vaccination During Pregnancy or Postpartum.

Infant Antibodies After Maternal COVID-19 Vaccination During Pregnancy or Postpartum.

Journal: Pediatrics

Published: December 10, 2024

Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus.

Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 01, 2024

Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.

Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.

Journal: AIDS and behavior

Published: June 18, 2024

Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.

Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.

Journal: The lancet. HIV

Published: May 28, 2024

Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.

Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.

Journal: Pediatrics

Published: December 13, 2023

Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.

Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.

Journal: Journal of the International AIDS Society

Published: May 19, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026